Radiation's hidden toll: new study tracks late effects in NPC survivors
NCT ID NCT02597426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 108 nasopharyngeal cancer survivors who had radiation and chemotherapy at least four years ago. Researchers are measuring long-term side effects like hormone problems, hearing loss, and memory issues using blood tests, cognitive exams, and quality-of-life surveys. The goal is to better understand and manage these late effects, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand and manage the long-term side effects of radiation for nasopharyngeal cancer survivors.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve outcomes. Results may not apply to all patients or newer radiation techniques.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
108 people
The number who actually took part.
- Start date
-
Jun 2015
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All patients with a previous diagnosis of NPC treated with curative intent who are alive and disease free with a minimum of four years of follow up following completion of treatment * Received treatment with IMRT * Age 18 or above, no upper limit * Ability to comply with the protocol Exclusion Criteria: * History of recurrent nasopharyngeal disease * A history of any physical, psychological or social condition which would impair with the ability of the patient to cooperate in this study * Unable to provide consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?
- Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
- Can an experimental drug shrink advanced solid tumors?
- Can a targeted therapy replace harsh chemo in nasopharyngeal cancer?
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test